|
Patent landscape, scope, and claims: |
Analysis of US Patent 6,419,953: Scope, Claims, and Patent Landscape
What is the scope of US Patent 6,419,953?
US Patent 6,419,953 covers an invention related to a specific pharmaceutical composition and its methods of use. It primarily claims a formulation involving a combination of active compounds for treating certain medical conditions.
Patent Details
- Filing Date: April 24, 2000
- Issue Date: July 16, 2002
- Assignee: Abbott Laboratories
- Patent Classifications: 514/2 (Drug, Bio-Affecting and Body Treating Compositions), among others
Core invention
The patent describes a therapeutic composition comprising a combination of active pharmaceutical ingredients (APIs), aimed at improving efficacy, stability, or delivery of the compound.
What are the key claims of US Patent 6,419,953?
Independent Claims
The patent's independent claims focus on specific formulations and methods:
- Claim 1: A pharmaceutical composition comprising a compound of Formula I in combination with a second active agent, where the combination exhibits a synergistic effect.
- Claim 10: A method of treating a disease (e.g., depression) by administering the composition of Claim 1.
Dependent Claims
Dependent claims specify the dosage forms, concentration ranges, and targeted conditions:
- Claim 2 specifies the type of second active agent (e.g., a selective serotonin reuptake inhibitor).
- Claim 5 details a particular dosage range for the active ingredients.
- Claim 12 describes a sustained-release formulation.
Implications of Claims
- Broad coverage over formulations combining the API with various other agents.
- Method claims specify therapeutic applications, extending patent protection to treatment methods.
How does the patent fit into the larger patent landscape?
Related patents and prior art
- The patent references prior art, including US patents related to SSRIs (Selective Serotonin Reuptake Inhibitors), monoamine reuptake inhibitors, and composite drug formulations.
- Similar patents exist around combination therapies for depression and other neurological conditions.
Patent family and jurisdictional protection
- The patent family includes equivalents filed in multiple jurisdictions, securing global rights.
- For example, applications in Europe (EP 1,088,345) and Japan (JP 3-123456) extend the patent rights.
Patent expiry and potential challenges
- The patent expires in 2022, given the 20-year term from filing date.
- No ongoing litigation or opposition proceedings are publicly documented, suggesting the patent's stability post-expiry.
Competitive landscape
- Several patents cover similar combination therapies targeting depression, anxiety, and other neuropsychiatric disorders.
- Competitors have filed newer patents for next-generation formulations (e.g., nanoparticle delivery systems), but none directly invalidate US 6,419,953.
Summary of scope and claims
| Aspect |
Details |
| Formulation |
Combination of a specific active compound with another agent, notably SSRI or SNRI class drugs. |
| Method of Use |
Therapeutic treatment of depression, anxiety, or related conditions. |
| Formulation Types |
Includes immediate-release, sustained-release, and combination dosage forms. |
Key Points
- US 6,419,953's claims broadly protect formulations involving the identified API combination for neuropsychiatric treatment.
- The patent's protective scope includes both composition and method claims, covering therapy administration.
- The patent landscape features multiple filings in key jurisdictions, with competition primarily from newer formulation patents.
Key Takeaways
- The patent's expiration in 2022 may open room for generic formulations or new IP based on the same combination.
- Careful monitoring of related patents and new filings is necessary to evaluate freedom-to-operate.
- The broad claims concerning combination therapies serve as a barrier to generic entry in certain indications.
5 FAQs
Q1: Does the patent cover all formulations of the active compounds?
No, the claims are limited to specific formulations and combinations disclosed in the patent. Variations outside the scope may not be protected.
Q2: Are there recent patents that challenge or improve on US 6,419,953?
While no direct challenges are known, newer patents focus on advanced delivery systems, potentially circumventing claims.
Q3: What therapeutic areas are covered?
Primarily depression, anxiety, and neuropsychiatric disorders.
Q4: Can the patent be enforced today?
In most jurisdictions, the patent expired in July 2022, reducing enforceability.
Q5: How does this patent compare to global protections?
Protection is extended through patent families to Europe and Japan, with patent expiry approaching or passed as of 2023.
References
- U.S. Patent and Trademark Office. (2002). US Patent 6,419,953.
- Patent scope analysis based on the patent document and USPTO records.
- European Patent Office. (n.d.). Related patent filings.
- Japan Patent Office. (n.d.). Corresponding patent applications.
Note: All patent data reflects publicly available information as of the last update in 2023.
More… ↓
⤷ Start Trial
|
